A modeling study finds diagnostic and biomarker bottlenecks sharply limit access to amyloid-targeting Alzheimer’s therapies in China. Even with an unconstrained pool of more than 14 million older adults potentially eligible, constraints restrict practical access to roughly 40,000 people. The meta-analysis and modeling identify that eligibility is primarily limited by how patients are diagnosed and whether they can complete required biomarker assessments. For health system planners and therapy stakeholders, the paper quantifies the gap between theoretical demand and real-world treatment pathways. The result frames reimbursement and testing capacity as major determinants of treatment reach, not just drug availability.
Get the Daily Brief